Compare iShares Gold Trust (IAU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Twist Bioscience Corp — how do they compare? iShares Gold Trust trades at $82.79, while Twist Bioscience Corp trades at $124.49 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| IAU | TWST | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $124.88 |
52-Week Low | $62.49 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, is trading at $83.305, up 0.96% with a bullish technical signal overall. The ETF benefits from gold's recent momentum as spot gold approaches $4,430/oz amid cooling inflation data and geopolitical tensions. Moving averages show bullish alignment while oscillators indicate some overbought conditions. Recent news highlights gold's safe-haven appeal with institutional buying and positive price forecasts.
The outlook remains positive given gold's role as an inflation hedge and safe-haven asset, supported by central bank demand and favorable CPI data. Risks include potential Fed policy shifts and dollar strength. Conservative investors favor IAU for its low 0.25% expense ratio and lower volatility compared to mining equities.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
